Full Text | PDF

J Cancer 2016; 7(13):1861-1866. doi:10.7150/jca.16279 This issue Cite

Research Paper

FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study

SJ Rombouts^1,2, TH Mungroop¹, MN Heilmann³, HW van Laarhoven³, OR Busch¹, IQ Molenaar^1,2, MG Besselink¹, JW Wilmink^{3 ✉}

1. Department of Surgery, Academic Medical Center Amsterdam, PO Box 22660, 1100 DD Amsterdam, The Netherlands
2. Department of Surgery, University Medical Center Utrecht, PO box 85500, 3508 GA Utrecht, The Netherlands
3. Department of Medical Oncology, Academic Medical Center Amsterdam, PO Box 22660, 1100 DD Amsterdam, The Netherlands

✉ Corresponding author: J.W. Wilmink, MD, PhD, Academic Medical Center Amsterdam, Department of Medical Oncology, G4-212, PO Box 22660, 1100 DD Amsterdam, The Netherlands. E-mail: j.w.wilminknl. Tel.: +31 20 566 9111

Abstract

Introduction: FOLFIRINOX is emerging as new standard of care for fit patients with locally advanced pancreatic cancer (LAPC) and metastatic pancreatic cancer (MPC). However, some of the physicians are reluctant to use FOLFIRINOX due to high toxicity rates reported in earlier studies. We reviewed our experience with FOLFIRINOX in LAPC and MPC, focussing on dose adjustments, toxicity and efficacy.

Methods: We reviewed all patients with LAPC or MPC treated with FOLFIRINOX in our institution between April 2011 and December 2015. Unresectability (stage III and IV) was determined by the institution's multidisciplinary team for pancreatic cancer.

Results: Fifty patients (18 LAPC and 32 MPC) were enrolled, with a median age of 55 years (IQR 49-66) and WHO performance status of 0/1. FOLFIRINOX was given as first-line treatment in 82% of patients. Dose modifications were applied in 90% of patients. The median number of completed cycles was 8 (IQR 5-9). Grade 3-4 toxicity occurred in 52% and grade 5 toxicity in 2%. The response rate was 25% (12% in LAPC, 32% in MPC). Median overall survival and progression-free survival were 14.8 and 10.3 months in LAPC, and 9.0 and 5.9 months in MPC, respectively. Overall 1- and 2-year survival was 65% and 10% in LAPC and 40% and 5% in MPC. Within the LAPC group, 6 patients (33%) underwent local ablative therapy and 1 patient (6%) a resection, leading to a median survival of 21.8 months.

Conclusion: FOLFIRINOX treatment with nearly routine dose modification was associated with acceptable toxicity rates, relatively high response rates and an encouraging overall survival.

Keywords: FOLFIRINOX, pancreatic cancer, advanced stage, stage III and IV, toxicity, efficacy

Citation styles

©2024 Ivyspring International Publisher. Terms of use